PLX AMEX
Hackensack, NJ 07601
US
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bashan Dror | P-Purchase | 56,000 | $1.81 | 2025-12-19 |
| Bar-Shalev Amos | S-Sale | 168 | $1.87 | 2025-11-18 |
| Melincoff Gwen A | A-Award | 15,000 | $1.64 | 2025-09-03 |
| Forster Eliot | A-Award | 15,000 | $1.64 | 2025-09-03 |
| Forster Eliot | A-Award | 7,500 | — | 2025-09-03 |